Morgan Stanley Novavax Inc Call Options Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding NVAX
# of Institutions
243Shares Held
76.1MCall Options Held
5.06MPut Options Held
7.19M-
State Street Corp Boston, MA16.9MShares$204 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.5MShares$163 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.43MShares$114 Million0.0% of portfolio
-
Shah Capital Management8.12MShares$97.9 Million19.75% of portfolio
-
Geode Capital Management, LLC Boston, MA2.59MShares$31.2 Million0.0% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $943M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...